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ESaphenous Vein Graft Intervention
Discussion on Acute Vein Graft
Occlusion Intervention
We read with interest the State-of-the-Art paper on saphenous
vein graft (SVG) intervention by Lee et al. (1), and commend the
authors for a comprehensive review.
We would like to highlight that the review failed to mention the
management of ST-segment elevation myocardial infarction due
to acute SVG occlusion. Retrospective data (2,3) have confirmed
his area remains a particularly high-risk subset of SVG interven-
ion, with 30-day mortality at 14.3% and major adverse cardiac
vents rate of 36.8% at 1 year. These are significantly worse than
ontemporary outcomes of acute coronary syndrome from coronary
rtery culprit lesions. We previously presented (4) a case of an
4-year-old patient with an ST-segment elevation myocardial
nfarction of a thrombotic occlusion in the SVG to the posterior
escending artery, during which difficulty was encountered in
estoring and maintaining flow in the culprit vessel. Significant
ffort was focused on preventing no-reflow with: 1) continuation of
he upstream tirofiban infusion; and 2) manual (Export catheter,
edtronic Inc., Minneapolis, Minnesota) and mechanical throm-
ectomy (Angiojet rheolytic thrombectomy catheter, Medrad Inc.,
arrendale, Philadelphia). A distal embolic protection device
Emboshield Abbott Vascular, Santa Clara, California) was deliv-
red distal to the culprit lesion before the placement of a bare-
etal stent. The stent nonetheless led to no-reflow, necessitating
reatment with adenosine, verapamil, and nitrate intracoronary
nfusion through a local delivery balloon (ClearWay RX, Atrium
edical, Hudson, New Hampshire). The final result was TIMI
Thrombolysis In Myocardial Infarction) flow grade 3 with no
ocal complication. A 12-month clinical follow-up revealed no
eintervention or rehospitalization.
We feel that acute SVG occlusion deserves a special mention.
here is currently little data applicable to this group of patients, as
irtually all trials on the aforementioned pharmacotherapy (i.e.,
Ib/IIIa inhibitors, adenosine, verapamil) and devices (thrombus
spiration and distal embolic protection) excluded patients with
cute SVG occlusion. The significant thrombus burden in the
ulprit vessel makes a satisfactory procedural outcome difficult and
he resulting compromised epicardial flow impairs long-term
utcome (5). It is not foreseeable that robust evidence-based
uidelines will ever become available given this relatively infre-
uent occurrence. Interventional cardiologists may be resigned to
xtrapolate data from research on SVG and acute coronary
yndrome interventions and be resourceful in approaching these
esions using all the tools that are available in interventional
ardiology.
Karl Poon, MBBS
lex Roati, MBBS
arren L. Walters, MBBS, MPhilThe Prince Charles Hospital
ardiology Program
ode Road
hermside, Queensland 4032
ustralia
-mail: karlkcpoon@bigpond.com
doi:10.1016/j.jcin.2011.09.004
REFERENCES
1. Lee MS, Park SJ, Kandzari DE, et al. Saphenous vein graft intervention.
J Am Coll Cardiol Intv 2011;4:831–43.
2. Gaglia MA Jr., Torguson R, Xue Z, et al. Outcomes of patients with
acute myocardial infarction from a saphenous vein graft culprit under-
going percutaneous coronary intervention. Catheter Cardiovasc Interv
2011;78:23–9.
3. Abdel-Karim AR, Banerjee S, Brilakis ES. Percutaneous intervention of
acutely occluded saphenous vein grafts: contemporary techniques and
outcomes. J Invasive Cardiol 2010;6:253–7.
4. Poon K. Saphenous Vein Graft Acute Occlusion Intervention. Abstract
presented at: EuroPCR 2011; May 17–20, 2011; Paris. Available at:
http://www.pcronline.com.
5. Valgimigli M, Campo G, Malagutti P, et al. Persistent coronary no flow
after wire insertion is an early and readily available mortality risk factor
despite successful mechanical intervention in acute myocardial infarc-
tion: a pooled analysis from the STRATEGY (Single High-Dose Bolus
Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-
Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY
(Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus
Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in
Acute Myocardial Infarction Study) trials. J Am Coll Cardiol Intv
2011;4:51–62.
Reply
We are grateful to Drs. Poon, Roati, and Walters for their interest
in our State-of-the-Art paper (1). Their case highlights the
complexities encountered during treatment of ST-segment eleva-
tion myocardial infarction (STEMI) due to saphenous vein graft
(SVG) thrombosis.
Acute occlusion of SVGs is commonly associated with extensive
atherosclerotic and thrombotic burden, which increases the risk of
distal embolization and no-reflow and, thus, death and myocardial
infarction (2). Aged SVGs develop a form of accelerated athero-
sclerosis in which the plaque composition is highly friable, often
described as having the consistency of “gruel” or “cottage cheese.”
As a result, glycoprotein IIb/IIIa inhibitors are ineffective, and
embolic protection devices remain the default therapy to prevent
periprocedural complications. Randomized trials have demon-
strated that, although these devices are helpful, they are
incapable of preventing all instances of distal embolization (3).
These considerations are likely to be even more relevant in the
case of an occluded SVG with STEMI, and once the SVG
occludes distally—given the lack of side branches—the SVG
often backfills extensively with thrombus. Fortunately, SVG oc-
clusion is responsible for 5% of STEMI (34 of 3,602 infarctions
in the HORIZONS-AMI [Harmonizing Outcomes with Revas-
